KR20240060625A - 암 치료를 위한 삼중제 요법 - Google Patents

암 치료를 위한 삼중제 요법 Download PDF

Info

Publication number
KR20240060625A
KR20240060625A KR1020247010862A KR20247010862A KR20240060625A KR 20240060625 A KR20240060625 A KR 20240060625A KR 1020247010862 A KR1020247010862 A KR 1020247010862A KR 20247010862 A KR20247010862 A KR 20247010862A KR 20240060625 A KR20240060625 A KR 20240060625A
Authority
KR
South Korea
Prior art keywords
cancer
tumor
dose
gefitinib
tamoxifen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247010862A
Other languages
English (en)
Korean (ko)
Inventor
래리 와이젠탈
윌리엄 그레이스
Original Assignee
사이토메트릭 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이토메트릭 테라퓨틱스, 인크. filed Critical 사이토메트릭 테라퓨틱스, 인크.
Publication of KR20240060625A publication Critical patent/KR20240060625A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247010862A 2021-09-15 2022-09-15 암 치료를 위한 삼중제 요법 Pending KR20240060625A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163244412P 2021-09-15 2021-09-15
US63/244,412 2021-09-15
PCT/US2022/043601 WO2023043883A1 (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Publications (1)

Publication Number Publication Date
KR20240060625A true KR20240060625A (ko) 2024-05-08

Family

ID=85603487

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247010862A Pending KR20240060625A (ko) 2021-09-15 2022-09-15 암 치료를 위한 삼중제 요법

Country Status (10)

Country Link
US (1) US12611411B2 (https=)
EP (1) EP4401720A4 (https=)
JP (1) JP2024531765A (https=)
KR (1) KR20240060625A (https=)
CN (1) CN118159262A (https=)
AU (1) AU2022345084A1 (https=)
CA (1) CA3231639A1 (https=)
IL (1) IL311229A (https=)
MX (1) MX2024003333A (https=)
WO (1) WO2023043883A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2644194T3 (en) * 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US20100189683A1 (en) 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101874390B1 (ko) * 2013-09-26 2018-07-04 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물

Also Published As

Publication number Publication date
JP2024531765A (ja) 2024-08-29
CA3231639A1 (en) 2023-03-23
EP4401720A4 (en) 2025-07-30
CN118159262A (zh) 2024-06-07
IL311229A (en) 2024-05-01
MX2024003333A (es) 2024-05-20
US20250127791A1 (en) 2025-04-24
WO2023043883A1 (en) 2023-03-23
US12611411B2 (en) 2026-04-28
AU2022345084A1 (en) 2024-03-28
EP4401720A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
Morabito et al. Treatment of small cell lung cancer
Choudhury et al. A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
WO2018234879A1 (en) USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
TW202523284A (zh) 用於治療子宮內膜癌的方法、組成物和組合
CN109475629A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
JP2019521971A (ja) がんの処置
JP2019502741A (ja) がんを処置するための方法
BR112017028287A2 (en) COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT
Kelley et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
Toyooka et al. A multicenter randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non–small cell lung cancer
Hayat Brain metastases from primary tumors, volume 3: epidemiology, biology, and therapy of melanoma and other cancers
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
Stathopoulos et al. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects
CA3135165A1 (en) Methods of treating cancer with chk1 inhibitors
JP7303205B2 (ja) 胆道癌を処置するための方法および併用療法
TW201907916A (zh) 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑
KR20240060625A (ko) 암 치료를 위한 삼중제 요법
CN120936347A (zh) 非小细胞肺癌的治疗
JP2025523801A (ja) 併用療法
WO2019139581A1 (en) Methods and combination therapy to treat cancer
JP2022522994A (ja) がんの処置のための組合せ物
Patel et al. Blood cancer: Advances in clinical research
RU2793543C2 (ru) Способы и комбинированное терапевтическое средство для лечения рака желчных протоков

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000